Last quarter (Q2 2026), KalVista Pharmaceuticals's total revenue was $13.69M, an increase of Infinity% from the same quarter last year. In Q2, KalVista Pharmaceuticals's net income was $-49.48M. See KalVista Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ -86.17M	$ 0.00	$ 0.00	$ -41.29M
Operating Expenses	$ 188.00M	$ 54.28M	$ 110.87M	$ 96.61M	$ 16.64M
Depreciation and Amortization	$ 941.00K	$ 816.00K	$ 718.00K	$ 564.00K	$ 537.00K
EBITDA	$ -173.33M	$ -134.28M	$ -94.37M	$ -80.75M	$ -57.39M
Operating Income	$ -188.00M	$ -140.44M	$ -110.87M	$ -96.61M	$ -57.92M
Other Income/Expenses	$ 7.94M	$ 5.35M	$ 17.96M	$ 14.27M	$ 11.68M
Pretax Income	$ -180.05M	$ -135.10M	$ -92.91M	$ -82.34M	$ -46.24M
Net Income	$ -183.44M	$ -126.64M	$ -92.91M	$ -82.34M	$ -46.24M
Per Share Metrics
Basic EPS	$ -3.69	$ -3.44	$ -3.33	$ -3.36	$ -2.33
Diluted EPS	$ -3.69	$ -3.44	$ -3.33	$ -3.36	$ -2.33
Weighted Average Shares Outstanding	49.65M	36.79M	27.89M	24.47M	19.09M
Weighted Average Shares Outstanding (Diluted)	49.65M	36.79M	27.89M	24.47M	19.09M

Currency in USD

KalVista Pharmaceuticals Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing